Further analysis of PREVAIL： enzalutamide use in chemotherapy-naive men with metastatic castration- resistant prostate cancer

作     者：Jeanny B Aragon-Ching 

作者机构：Department of Medicine Division of Hematology andOncology George Washington University MedicalCenter 2150 Pennsylvania Avenue NW WashingtonDC 20037 USA. 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2014年第16卷第6期

页      面：803-804页

核心收录：

学科分类：0710[理学-生物学] 0832[工学-食品科学与工程（可授工学、农学学位）] 1002[医学-临床医学] 07[理学] 08[工学] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 

主　　题：ABIRATERONE DOCETAXEL 

摘      要：PREVAIL was a phase III multinational, double-blind, placebo-controlled trial that enrolled chemotherapy-naive men with metastatic castration-resistant prostate cancer （mCRPC）, which showed remarkable improvement in co-primary endpoints with an overall 81% reduction in the risk of radiographic progression, as well as 29% reduction in the risk of death in favor of the enzalutamide arm over placebo. All secondary endpoints including time to subsequent chemotherapy initiation and prostate specific antigen （PSA） progression were in favor of the enzalutamide arm. The results of PREVAIL shows the utility of enzalutamide that would likely soon expand the indication to asymptomatic or minimally symptomatic men with mCRPC not previously treated with chemotherapy.